0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover727.96%IV-198.51%PremiumMay 16, 2025Expiry Date0.66Intrinsic Value100Multiplier13DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.5340Delta0.8511Gamma0.45Leverage Ratio-0.0070Theta-0.0003Rho-0.24Eff Leverage0.0003Vega
Renovaro Stock Discussion
Renovaro's New AI Partnership Targets Breakthrough in Early-Stage Lung Cancer Detection Technology
Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
Tuesday, 22nd April at 9:20 am
LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leadi...
Major AI Breakthrough: Renovaro-BioSymetrics Merger Creates Powerhouse in Precision Medicine
Merger Crisis: Renovaro Threatens Legal Action After Predictive Oncology Backs Out
Can Renovaro's AI Oncology Merger Unlock Value From 150,000+ Tumor Samples?
Can Renovaro's AI Biotech Merger Transform Drug Discovery? Major Pharma Already Onboard
No comment yet